1616776-04-5

Basic information

• Product Name: cabazitaxel-2’-p-nitrophenylcarbonate
• Synonyms: cabazitaxel-2’-p-nitrophenylcarbonate
• CAS NO: 1616776-04-5
• Molecular Weight: 1001.05
• Mol File: 1616776-04-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: cabazitaxel-2’-p-nitrophenylcarbonate(CAS DataBase Reference)
• NIST Chemistry Reference: cabazitaxel-2’-p-nitrophenylcarbonate(1616776-04-5)
• EPA Substance Registry System: cabazitaxel-2’-p-nitrophenylcarbonate(1616776-04-5)

Safety Data

• Hazardous Substances Data: 1616776-04-5(Hazardous Substances Data)

Upstream product

• 183133-96-2 carbazitaxel 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 1616835-66-5 C₅₇H₇₃N₃O₁₅S₂ 

Relevant articles and documents

Taxane prodrug, preparation method and application thereof

The invention discloses a taxane prodrug, which has a structure of Y1-R-Y2, wherein the Y1 and the Y2 are docetaxel or cabazitaxel, R comprises a specific connecting bond for environmental response intumor cells, and the taxane prodrug is generated by car

TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Targeted Conjugates Encapsulated in Particles and Formulations Thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.